{"id":"dupilumab-dupixent","safety":{"commonSideEffects":[{"rate":"10-20","effect":"Injection site reactions"},{"rate":"10-15","effect":"Conjunctivitis"},{"rate":"5-10","effect":"Headache"},{"rate":"5","effect":"Oropharyngeal pain"},{"rate":"1-3","effect":"Herpes simplex infection"}]},"_chembl":{"chemblId":"CHEMBL2108675","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Dupilumab binds to IL-4 receptor alpha, a shared component of IL-4 and IL-13 signaling pathways that drive type 2 inflammatory responses. By blocking this receptor, it suppresses the production of IgE antibodies, reduces eosinophil recruitment, and decreases inflammatory mediator release. This mechanism addresses the underlying pathophysiology of multiple type 2 inflammatory diseases including atopic dermatitis, asthma, and eosinophilic conditions.","oneSentence":"Dupilumab is a monoclonal antibody that blocks the IL-4 receptor alpha subunit, inhibiting signaling of IL-4 and IL-13 cytokines to reduce type 2 inflammation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:10:13.394Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Moderate-to-severe atopic dermatitis"},{"name":"Moderate-to-severe asthma with type 2 inflammation"},{"name":"Eosinophilic esophagitis"},{"name":"Chronic rhinosinusitis with nasal polyps"}]},"trialDetails":[{"nctId":"NCT06389136","phase":"PHASE3","title":"A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab","status":"RECRUITING","sponsor":"AbbVie","startDate":"2024-06-14","conditions":"Atopic Dermatitis","enrollment":200},{"nctId":"NCT07027527","phase":"PHASE1","title":"An Active Comparator Safety Study Evaluating the Combination of APG777 + APG990 in Moderate-to-Severe Atopic Dermatitis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Apogee Therapeutics, Inc.","startDate":"2025-06-04","conditions":"Atopic Dermatitis","enrollment":86},{"nctId":"NCT06461897","phase":"PHASE3","title":"A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis","status":"RECRUITING","sponsor":"AbbVie","startDate":"2024-08-19","conditions":"Atopic Dermatitis","enrollment":675},{"nctId":"NCT07053423","phase":"PHASE4","title":"A Study to Investigate Airway Inflammation With Dupilumab Subcutaneously in Participants Aged ≥40 to ≤85 Years With Chronic Obstructive Pulmonary Disease.","status":"RECRUITING","sponsor":"Sanofi","startDate":"2025-09-22","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":218},{"nctId":"NCT05263206","phase":"PHASE3","title":"Efficacy and Safety of Subcutaneous Dupilumab for the Treatment of Adult Participants With Chronic Pruritus of Unknown Origin (CPUO) (LIBERTY-CPUO-CHIC)","status":"RECRUITING","sponsor":"Sanofi","startDate":"2022-02-15","conditions":"Pruritus","enrollment":284},{"nctId":"NCT05857228","phase":"","title":"Viral and Epigenetic Influences in CRSwNP","status":"ACTIVE_NOT_RECRUITING","sponsor":"Centre hospitalier de l'Université de Montréal (CHUM)","startDate":"2023-05-18","conditions":"Chronic Rhinosinusitis (Diagnosis)","enrollment":60},{"nctId":"NCT06693531","phase":"","title":"A U.S. Registry of Eosinophilic Esophagitis Pediatric, Adolescent and Adult Patients Treated With DUPIXENT® As Standard of Care","status":"RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2024-11-22","conditions":"Eosinophilic Esophagitis (EoE)","enrollment":350},{"nctId":"NCT05097287","phase":"PHASE4","title":"Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Adult Patients With Uncontrolled Moderate to Severe Asthma","status":"RECRUITING","sponsor":"Sanofi","startDate":"2021-12-16","conditions":"Asthma","enrollment":1324},{"nctId":"NCT06191315","phase":"PHASE3","title":"Efficacy and Safety of Subcutaneous Dupilumab in Participants With Asthma/Asthmatic Wheeze Aged 2 to <6 Years (LIBERTY ASTHMA TREKIDS)","status":"RECRUITING","sponsor":"Sanofi","startDate":"2024-01-03","conditions":"Wheezing, Asthma","enrollment":90},{"nctId":"NCT07380711","phase":"","title":"Long-term Real-world Study of Dupilumab in COPD : Patient Characteristics, Safety and Patient-reported Outcomes","status":"RECRUITING","sponsor":"Sanofi","startDate":"2026-01-28","conditions":"Chronic Obstructive Pulmonary Disease COPD","enrollment":500},{"nctId":"NCT06881251","phase":"PHASE2","title":"A Study of JNJ-95475939 in the Treatment of Participants With Moderate to Severe Atopic Dermatitis (AD)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2025-02-26","conditions":"Dermatitis, Atopic","enrollment":256},{"nctId":"NCT07467564","phase":"","title":"The Impact of Dupilumab Treatment on Anxiety and Depression Symptoms in Patients With Moderate-to-Severe Atopic Dermatitis","status":"RECRUITING","sponsor":"Sanofi","startDate":"2026-02-24","conditions":"Atopic Dermatitis","enrollment":184},{"nctId":"NCT07330934","phase":"PHASE2","title":"A Study to Evaluate Efficacy and Safety of IBI356 in Participants With Moderate to Severe Atopic Dermatitis","status":"RECRUITING","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","startDate":"2025-12-31","conditions":"Atopic Dermatitis","enrollment":403},{"nctId":"NCT07411755","phase":"PHASE1","title":"A Phase 1 Study of GS101 Injection","status":"RECRUITING","sponsor":"Jiangsu Genscend Biopharmaceutical Co., Ltd","startDate":"2026-03-05","conditions":"Atopic Dermatitis (AD)","enrollment":294},{"nctId":"NCT06868212","phase":"PHASE3","title":"A Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-antihistamines","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2025-07-11","conditions":"Chronic Spontaneous Urticaria (CSU)","enrollment":400},{"nctId":"NCT06695897","phase":"","title":"A Non-interventional Observational Study to Assess Long-term Efficacy and Safety of Dupilumab for the Treatment of Patients (>= 12 Years) With Eosinophilic Esophagitis Under Real-world-conditions in Germany","status":"RECRUITING","sponsor":"Sanofi","startDate":"2024-12-02","conditions":"Eosinophilic Esophagitis","enrollment":150},{"nctId":"NCT05720325","phase":"PHASE2","title":"Dupilumab Effects Against Aeroallergen Challenge","status":"RECRUITING","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2023-03-29","conditions":"Asthma, Allergic","enrollment":88},{"nctId":"NCT04206553","phase":"PHASE2, PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Bullous Pemphigoid","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2020-10-28","conditions":"Bullous Pemphigoid","enrollment":106},{"nctId":"NCT07408219","phase":"","title":"A Real-world Study of Remibrutinib in Chronic Spontaneous Urticaria Patients","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2026-01-17","conditions":"Chronic Spontaneous Urticaria","enrollment":350},{"nctId":"NCT07448363","phase":"","title":"Atopic Dermatitis Treated With Dupilumab and JAK Inhibitors in Costa Rica","status":"NOT_YET_RECRUITING","sponsor":"Caja Costarricense de Seguro Social","startDate":"2026-05","conditions":"Atopic Dermatitis, Atopic Dermatitis (AD), Atopic Dermatitis (Eczema)","enrollment":50},{"nctId":"NCT07112378","phase":"PHASE3","title":"A Study of Dupilumab in Small Children With an Allergic Condition of the Esophagus (Food Pipe): Eosinophilic Esophagitis","status":"RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2025-11-10","conditions":"Eosinophilic Esophagitis (EoE)","enrollment":20},{"nctId":"NCT04173442","phase":"","title":"Post-authorization Safety Study in North America to Monitor Pregnancy and Infant Outcomes Following Administration of Dupilumab During Planned or Unexpected Pregnancy","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2018-10-24","conditions":"Atopic Dermatitis (AD), Asthma","enrollment":581},{"nctId":"NCT07309614","phase":"PHASE3","title":"A Study Assessing the Effect of Dupilumab on Inducing Clinical Remission in Asthma","status":"RECRUITING","sponsor":"Université de Sherbrooke","startDate":"2026-01-29","conditions":"Asthma Control","enrollment":150},{"nctId":"NCT07277322","phase":"PHASE1, PHASE2","title":"Neoadjuvant Dupilumab and Toripalimab in MSS CRC Subjects With Resectable Liver Metastases","status":"NOT_YET_RECRUITING","sponsor":"Dan Feng","startDate":"2026-03-15","conditions":"Metastatic Colorectal Cancer, Liver Metastases","enrollment":24},{"nctId":"NCT03935971","phase":"PHASE4","title":"The Effects of Dupilumab on Allergic Contact Dermatitis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2019-12-18","conditions":"Allergic Contact Dermatitis","enrollment":17},{"nctId":"NCT04287621","phase":"","title":"Registry of Asthma Patients Initiating DUPIXENT®","status":"ACTIVE_NOT_RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2020-03-02","conditions":"Asthma","enrollment":718},{"nctId":"NCT05369403","phase":"PHASE3","title":"A Study of Lebrikizumab (LY3650150) in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Previously Treated With Dupilumab","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2022-12-19","conditions":"Atopic Dermatitis","enrollment":86},{"nctId":"NCT06415175","phase":"","title":"Study in Paediatric Patients With Atopic Dermatitis Treated With Dupilumab in Spain","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2024-11-14","conditions":"Atopic Dermatitis","enrollment":143},{"nctId":"NCT03694158","phase":"PHASE4","title":"Investigating Dupilumab's Effect in Asthma by Genotype","status":"ACTIVE_NOT_RECRUITING","sponsor":"Boston Children's Hospital","startDate":"2021-09-08","conditions":"Asthma","enrollment":150},{"nctId":"NCT05866562","phase":"PHASE2","title":"Dupilumab in the Treatment of Pediatric Alopecia Areata","status":"RECRUITING","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2024-07-11","conditions":"Alopecia Areata","enrollment":76},{"nctId":"NCT05436535","phase":"PHASE4","title":"Longitudinal Endotyping Of Atopic Dermatitis Through Transcriptomic Skin Analysis","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2022-11-21","conditions":"Atopic Dermatitis","enrollment":433},{"nctId":"NCT05964465","phase":"PHASE4","title":"Mechanisms of Smell Improvement With Dupilumab.","status":"COMPLETED","sponsor":"Medical University of South Carolina","startDate":"2023-08-10","conditions":"Chronic Rhinosinusitis With Nasal Polyps","enrollment":60},{"nctId":"NCT07399067","phase":"PHASE2","title":"A Proof-of-Concept Study of IBI3002 in Patients With Moderate to Severe Atopic Dermatitis","status":"RECRUITING","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","startDate":"2026-02-06","conditions":"Atopic Dermatitis","enrollment":120},{"nctId":"NCT07316114","phase":"","title":"A Study to Describe the Real-world Effectiveness, Safety and Patterns of Use of Dupilumab in Patients With Chronic Spontaneous Urticaria","status":"RECRUITING","sponsor":"Sanofi","startDate":"2026-02-28","conditions":"Chronic Spontaneous Urticaria","enrollment":400},{"nctId":"NCT04550962","phase":"","title":"Description of Characteristics, Such as Age, Previous and Concurrent Treatments, Associated Diseases, of Patients With Asthma Treated With Dupilumab (DUPIXENT)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2020-11-02","conditions":"Asthma","enrollment":376},{"nctId":"NCT06039241","phase":"","title":"Real-world Effectiveness Study of Long-term Treatment With Dupilumab in Participants ≥6 Years With Atopic Dermatitis","status":"RECRUITING","sponsor":"Sanofi","startDate":"2023-03-07","conditions":"Atopic Dermatitis","enrollment":900},{"nctId":"NCT07386743","phase":"PHASE3","title":"A Phase III Study of GS101 Injection to Dupixent®","status":"NOT_YET_RECRUITING","sponsor":"Jiangsu Genscend Biopharmaceutical Co., Ltd","startDate":"2026-02","conditions":"Atopic Dermatitis (AD)","enrollment":572},{"nctId":"NCT06572228","phase":"PHASE4","title":"Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma","status":"RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2024-08-26","conditions":"Asthma","enrollment":250},{"nctId":"NCT05478824","phase":"","title":"IL13 Signaling in Allergic Asthma","status":"COMPLETED","sponsor":"Duke University","startDate":"2023-02-21","conditions":"Asthma, Allergic, Asthma, Obesity","enrollment":28},{"nctId":"NCT07358156","phase":"PHASE1","title":"A Study to Compare the Pharmacokinetics, Pharmacodynamic, Immunogenicity, and Safety of CKD-706 With US-Dupixent®, and EU-Dupixent® in Healthy Adult Participants.","status":"RECRUITING","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2026-02-09","conditions":"Atopic Dermatitis","enrollment":519},{"nctId":"NCT05246267","phase":"","title":"Dupilumab Treatment Effects in an Ethnically Diverse Population With Chronic Rhinosinusitis With Nasal Polyposis","status":"RECRUITING","sponsor":"Montefiore Medical Center","startDate":"2022-02-15","conditions":"Chronic Rhinosinusitis With Nasal Polyps","enrollment":60},{"nctId":"NCT07358234","phase":"EARLY_PHASE1","title":"Comparison of Eohilia With Dupixent on Esophagus Diameter in Patients With Eosinophilic Esophagitis.","status":"NOT_YET_RECRUITING","sponsor":"Mayo Clinic","startDate":"2026-02","conditions":"Eosinophilic Esophagitis (EoE)","enrollment":60},{"nctId":"NCT06687967","phase":"PHASE3","title":"A Study to Investigate Improvement in Pruritus of Lichen Simplex Chronicus With Dupilumab Injections Compared With Placebo in Male and Female Participants Aged at Least 18 Years (STYLE 1)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2024-11-28","conditions":"Lichen Simplex Chronicus","enrollment":142},{"nctId":"NCT06687980","phase":"PHASE3","title":"A Study to Investigate Improvement in Pruritus of Lichen Simplex Chronicus With Dupilumab Injections Compared With Placebo in Male and Female Participants Aged at Least 18 Years (STYLE 2)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2024-11-25","conditions":"Lichen Simplex Chronicus","enrollment":138},{"nctId":"NCT07352566","phase":"PHASE4","title":"Utilization of a Microdevice for Psoriasis and Atopic Dermatitis","status":"NOT_YET_RECRUITING","sponsor":"University of California, San Francisco","startDate":"2026-01-01","conditions":"Psoriasis, Atopic Dermatitis","enrollment":10},{"nctId":"NCT05347771","phase":"PHASE2","title":"Prevention of Asthma Exacerbations Using Dupilumab in Urban Children and Adolescents","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2022-05-04","conditions":"Asthma","enrollment":240},{"nctId":"NCT06293053","phase":"PHASE3","title":"A Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants ≥6 Months to <18 Years of Age With Prurigo Nodularis","status":"RECRUITING","sponsor":"Sanofi","startDate":"2024-05-15","conditions":"Prurigo Nodularis","enrollment":18},{"nctId":"NCT06116526","phase":"PHASE4","title":"Dupilumab De-escalation in Pediatric Atopic Dermatitis","status":"RECRUITING","sponsor":"Johns Hopkins University","startDate":"2024-04-01","conditions":"Atopic Dermatitis","enrollment":30},{"nctId":"NCT06136767","phase":"","title":"Registry for Systemic Eczema Treatments","status":"RECRUITING","sponsor":"Johns Hopkins University","startDate":"2024-01-17","conditions":"Atopic Dermatitis","enrollment":400},{"nctId":"NCT07334496","phase":"PHASE1","title":"A Study to Evaluate the Biosimilarity of GLR1044 Injection and Dupilumab Injection (Dupixent®) in Healthy Adult Male Subjects","status":"NOT_YET_RECRUITING","sponsor":"Gan & Lee Pharmaceuticals.","startDate":"2026-03-09","conditions":"Biosimilarity","enrollment":198},{"nctId":"NCT06012448","phase":"PHASE4","title":"The Immunologic Effects of Dupilumab in the Treatment of Dermal Hypersensitivity Reaction","status":"COMPLETED","sponsor":"University of Michigan","startDate":"2023-10-02","conditions":"Dermal Hypersensitivity Reaction","enrollment":10},{"nctId":"NCT04148352","phase":"PHASE2","title":"Dupilumab and Milk OIT for the Treatment of Cow's Milk Allergy","status":"TERMINATED","sponsor":"Andrew J Long, PharmD","startDate":"2021-10-18","conditions":"Allergies Food Milk","enrollment":33},{"nctId":"NCT05590585","phase":"PHASE4","title":"Dupilumab in Adolescent and Adult Skin of Color Participants: Open-label Moderate-to-severe Eczema Trial","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2023-01-11","conditions":"Moderate-to-Severe Atopic Dermatitis, Atopic Eczema","enrollment":124},{"nctId":"NCT03428646","phase":"","title":"Study of Patients Receiving DUPIXENT® for Atopic Dermatitis (AD)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2018-04-06","conditions":"Dermatitis, Atopic","enrollment":858},{"nctId":"NCT06101095","phase":"PHASE4","title":"A Study Assessing Esophageal Function and Remodeling With Dupilumab Compared With Placebo for 24 Weeks Followed by 104 Weeks Open Label in Adult Participants With EoE (REMOdeling With Dupilumab in Eosinophilic Esophagitis Long-term Trial)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2023-11-29","conditions":"Eosinophilic Oesophagitis","enrollment":69},{"nctId":"NCT06393946","phase":"","title":"Study in Adults With Severe Chronic Rhinosinusitis With Nasal Polyposis Treated With Dupilumab in France","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2023-10-20","conditions":"Chronic Rhinosinusitis With Nasal Polyposis","enrollment":150},{"nctId":"NCT04684524","phase":"PHASE3","title":"Dupilumab in Allergic Fungal Rhinosinusitis (AFRS) (LIBERTY-AFRS-AI)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2020-12-01","conditions":"Allergic Fungal Rhinosinusitis","enrollment":62},{"nctId":"NCT07052396","phase":"","title":"Study to Evaluate Long-term Effectiveness and Safety, Patient Characteristics and Subjective Patient-reported Outcomes of Dupilumab in Patients With Chronic Obstructive Pulmonary Disease (COPD) Under Real-world Conditions","status":"RECRUITING","sponsor":"Sanofi","startDate":"2025-07-01","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":350},{"nctId":"NCT07276425","phase":"","title":"Early and Long-Term Efficacy and Immune Changes With Dupilumab in Prurigo Nodularis","status":"RECRUITING","sponsor":"UMC Utrecht","startDate":"2025-06-01","conditions":"Prurigo Nodularis (PN)","enrollment":40},{"nctId":"NCT05013450","phase":"PHASE1, PHASE2","title":"Dupilumab_Metastatic NSCLC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Thomas Marron","startDate":"2021-09-10","conditions":"Metastatic Non-small Cell Lung Cancer","enrollment":33},{"nctId":"NCT05731128","phase":"PHASE2","title":"A Study to Investigate the Efficacy and Safety of Dupilumab Therapy Compared With Placebo in Participants Aged ≥18 Years With Moderately to Severely Active Ulcerative Colitis With an Eosinophilic Phenotype (LIBERTY-UC SUCCEED (Study in UC for Clinical Efficacy Evaluation of Dupilumab))","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2023-01-12","conditions":"Colitis Ulcerative","enrollment":68},{"nctId":"NCT06352073","phase":"PHASE4","title":"Dupilumab for Eosinophilic Esophagitis With Severe Strictures","status":"ENROLLING_BY_INVITATION","sponsor":"University of North Carolina, Chapel Hill","startDate":"2024-05-16","conditions":"Eosinophilic Esophagitis, EoE","enrollment":30},{"nctId":"NCT06018441","phase":"","title":"A Study to Evaluate the Quality of Life in Male and Female Adult Participants With Severe Asthma Treated With Dupilumab in a Real-world Setting","status":"COMPLETED","sponsor":"Sanofi","startDate":"2023-10-03","conditions":"Asthma","enrollment":112},{"nctId":"NCT07268313","phase":"PHASE4","title":"Complete Remission After Treatment With Biologics for Nasal Polyps","status":"RECRUITING","sponsor":"Rigshospitalet, Denmark","startDate":"2025-04-03","conditions":"Nasal Polyps","enrollment":66},{"nctId":"NCT06477653","phase":"PHASE2","title":"Dupilumab as Add-On Therapy for Hypereosinophilic Syndrome With Partial Clinical Response to Eosinophil-Depleting Biologic Agents","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2025-02-05","conditions":"Hypereosinophilic Syndrome","enrollment":30},{"nctId":"NCT07091175","phase":"PHASE2","title":"Dupilumab Therapy in Nephrotic Syndrome in Children","status":"RECRUITING","sponsor":"National University Hospital, Singapore","startDate":"2025-11-27","conditions":"Nephrotic Syndrome in Children, Nephrotic Syndrome Steroid-Dependent","enrollment":66},{"nctId":"NCT07257835","phase":"","title":"Dupilumab Therapy for EGIDs","status":"RECRUITING","sponsor":"Children's Hospital of Fudan University","startDate":"2025-01-01","conditions":"Eosinophilic Gastrointestinal Disorders (EGIDs)","enrollment":20},{"nctId":"NCT07187089","phase":"PHASE4","title":"Study of Growth and Bone Mineral Density in Children With Atopic Dermatitis (AD) Treated With Dupilumab","status":"WITHDRAWN","sponsor":"Regeneron Pharmaceuticals","startDate":"2025-11-11","conditions":"Severe Atopic Dermatitis (AD)","enrollment":""},{"nctId":"NCT05526521","phase":"PHASE3","title":"A Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants ≥2 Years to <12 Years of Age With Uncontrolled Chronic Spontaneous Urticaria (CSU) (LIBERTY-CSU CUPIDKids)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2022-08-25","conditions":"Chronic Spontaneous Urticaria","enrollment":15},{"nctId":"NCT04256759","phase":"PHASE2","title":"Dupilumab for the Treatment of Moderate to Severe Chronic Hepatic Pruritus","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2020-09-01","conditions":"Pruritus","enrollment":9},{"nctId":"NCT03560466","phase":"PHASE3","title":"Assessment of the Safety and Efficacy of Dupilumab in Children With Asthma (Liberty Asthma Excursion)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2018-06-21","conditions":"Asthma","enrollment":378},{"nctId":"NCT05535738","phase":"PHASE2, PHASE3","title":"Using a Contact Dermatitis Model With Biologic Medications to Study Skin Inflammation","status":"RECRUITING","sponsor":"Wei-Che Ko","startDate":"2022-11-15","conditions":"Skin Inflammation, Allergic Contact Dermatitis","enrollment":45},{"nctId":"NCT03293030","phase":"PHASE4","title":"Immunogenetic Profiling of Dupilumab for the Treatment of Atopic Dermatitis","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2018-10-22","conditions":"Atopic Dermatitis, Atopic Dermatitis Eczema, Eczema","enrollment":17},{"nctId":"NCT06369467","phase":"PHASE1","title":"Short-Term Linvoseltamab Treatment on Top of Chronic Dupilumab Treatment for Adults With Severe Immunoglobulin E (IgE)-Mediated Food Allergy","status":"RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2024-05-17","conditions":"Food Allergy","enrollment":6},{"nctId":"NCT04743791","phase":"PHASE4","title":"Measuring the Effect of Dupilumab Treatment on Mucociliary Clearance (MCC) in Subjects With Moderate to Severe Asthma","status":"RECRUITING","sponsor":"Sally E. Wenzel MD","startDate":"2022-10-17","conditions":"Asthma","enrollment":30},{"nctId":"NCT05247866","phase":"PHASE4","title":"Efficacy of Dupilumab on Facilitated Food Introduction in Eosinophilic Esophagitis","status":"COMPLETED","sponsor":"Children's Hospital of Philadelphia","startDate":"2022-06-16","conditions":"Eosinophilic Esophagitis","enrollment":21},{"nctId":"NCT05268107","phase":"PHASE4","title":"Ethnic Differences in Mechanisms of Action of Dupilumab","status":"RECRUITING","sponsor":"University of Michigan","startDate":"2023-01-25","conditions":"Atopic Dermatitis","enrollment":30},{"nctId":"NCT03678545","phase":"PHASE2","title":"Dupilumab in Eosinophilic Gastritis","status":"COMPLETED","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2021-05-15","conditions":"Eosinophilic Gastritis, Eosinophilic Gastroenteritis","enrollment":41},{"nctId":"NCT04362501","phase":"PHASE2","title":"Efficacy of Dupilumab for Patients With Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2020-10-15","conditions":"Chronic Sinusitis","enrollment":33},{"nctId":"NCT04394351","phase":"PHASE3","title":"Study to Investigate the Efficacy and Safety of Dupilumab in Pediatric Patients With Active Eosinophilic Esophagitis (EoE)","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2020-09-01","conditions":"Eosinophilic Esophagitis (EoE)","enrollment":102},{"nctId":"NCT04998604","phase":"PHASE4","title":"EValuating trEatment RESponses of Dupilumab Versus Omalizumab in Type 2 Patients","status":"COMPLETED","sponsor":"Sanofi","startDate":"2021-09-27","conditions":"Chronic Rhinosinusitis With Nasal Polyps, Asthma","enrollment":360},{"nctId":"NCT06004986","phase":"PHASE4","title":"DUPIlumab Dose REDUCtion in Patients With Controlled Atopic Eczema","status":"RECRUITING","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2023-08-14","conditions":"Atopic Dermatitis, Atopic Dermatitis Eczema","enrollment":216},{"nctId":"NCT05831176","phase":"PHASE2","title":"A Study to Learn How Well Dupilumab Works in Adult and Adolescent Participants With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis and the Side Effects it May Have","status":"ACTIVE_NOT_RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2023-05-03","conditions":"Eosinophilic Gastritis (EoG), Eosinophilic Duodenitis (EoD), Eosinophilic Gastrointestinal Disease (EGID)","enrollment":22},{"nctId":"NCT06824649","phase":"PHASE4","title":"Biologics in Chronic Rhinosinusitis With Nasal Polyposis","status":"NOT_YET_RECRUITING","sponsor":"Medical University of South Carolina","startDate":"2026-03","conditions":"Chronic Sinusitis, Nasal Polyps","enrollment":504},{"nctId":"NCT05878093","phase":"PHASE3","title":"Dupilumab in Chinese Adult Participants With CRSwNP","status":"COMPLETED","sponsor":"Sanofi","startDate":"2023-05-16","conditions":"Chronic Rhinosinusitis With Nasal Polyps","enrollment":63},{"nctId":"NCT07187583","phase":"PHASE4","title":"Tapering of Biologics in Chronic Rhinosinusitis With Nasal Polyps","status":"RECRUITING","sponsor":"Rigshospitalet, Denmark","startDate":"2025-06-05","conditions":"Chronic Rhinosinusitis With Nasal Polyps","enrollment":135},{"nctId":"NCT04600362","phase":"PHASE2","title":"Study of Dupilumab to Demonstrate Efficacy in Subjects With Nummular Eczema","status":"ACTIVE_NOT_RECRUITING","sponsor":"Technical University of Munich","startDate":"2021-03-30","conditions":"Nummular Eczema","enrollment":70},{"nctId":"NCT04776694","phase":"","title":"Compassionate Use of Dupilumab","status":"APPROVED_FOR_MARKETING","sponsor":"Regeneron Pharmaceuticals","startDate":"","conditions":"Type 2 Inflammatory Disorders","enrollment":""},{"nctId":"NCT06226610","phase":"PHASE2","title":"Dupixent in Adults With Refractory Post-Burn Pruritus in an Ambulatory Clinic","status":"RECRUITING","sponsor":"Akron Children's Hospital","startDate":"2024-11-21","conditions":"Pruritis","enrollment":46},{"nctId":"NCT05976386","phase":"PHASE1","title":"Single Dose Comparability Study of New and Current Dupilumab Drug Products Subcutaneously Administered in Healthy Adults","status":"COMPLETED","sponsor":"Sanofi","startDate":"2021-06-08","conditions":"Healthy Volunteers","enrollment":182},{"nctId":"NCT04447417","phase":"PHASE4","title":"Dupilumab Skin Barrier Function Study in Atopic Dermatitis","status":"COMPLETED","sponsor":"Sanofi","startDate":"2020-07-16","conditions":"Atopic Dermatitis","enrollment":52},{"nctId":"NCT04202679","phase":"PHASE3","title":"Study of Dupilumab for the Treatment of Patients With Prurigo Nodularis, Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable (PRIME2)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2020-01-16","conditions":"Neurodermatitis","enrollment":160},{"nctId":"NCT04183335","phase":"PHASE3","title":"Study of Dupilumab for the Treatment of Patients With Prurigo Nodularis, Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable (LIBERTY-PN PRIME)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2019-12-12","conditions":"Neurodermatitis","enrollment":151},{"nctId":"NCT04033367","phase":"PHASE4","title":"SAR231893-LPS15497- \"Dupilumab Effect on Sleep in AD Patients\"","status":"COMPLETED","sponsor":"Sanofi","startDate":"2019-08-22","conditions":"Atopic Dermatitis","enrollment":188},{"nctId":"NCT04823130","phase":"PHASE4","title":"Dupilumab Effect on Pruritus Neuro-mechanisms in Patients With Atopic Dermatitis","status":"COMPLETED","sponsor":"Sanofi","startDate":"2021-04-22","conditions":"Dermatitis Atopic","enrollment":54},{"nctId":"NCT05991323","phase":"","title":"Real-World Effectiveness of Dupilumab in Patients With Prurigo Nodularis: An Observational Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2023-12-12","conditions":"Prurigo Nodularis","enrollment":100},{"nctId":"NCT05575037","phase":"PHASE2","title":"Mechanisms of Benefit of IL4RA Inhibition in Aspirin-Exacerbated Respiratory Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2023-08-01","conditions":"Nasal Polyps, Asthma, Aspirin-Induced, Aspirin-Exacerbated Respiratory Disease","enrollment":17},{"nctId":"NCT05624112","phase":"PHASE4","title":"Dupilumab Skin BArrier Function and LIpidomics STudy in Atopic Dermatitis in China","status":"COMPLETED","sponsor":"Sanofi","startDate":"2022-11-25","conditions":"Atopic Dermatitis, Dermatitis Atopic","enrollment":44},{"nctId":"NCT04718870","phase":"PHASE4","title":"Dupilumab-PEdiatric Skin Barrier Function and LIpidomics STudy in Patients With Atopic Dermatitis","status":"COMPLETED","sponsor":"Sanofi","startDate":"2021-02-19","conditions":"Dermatitis Atopic","enrollment":41},{"nctId":"NCT04678882","phase":"PHASE3","title":"Dupilumab in Japanese Patients With Atopic Dermatitis","status":"COMPLETED","sponsor":"Sanofi","startDate":"2021-01-15","conditions":"Atopic Dermatitis","enrollment":62}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Dupilumab/Dupixent","genericName":"Dupilumab/Dupixent","companyName":"McMaster University","companyId":"mcmaster-university","modality":"Biologic","firstApprovalDate":"","aiSummary":"Dupilumab is a monoclonal antibody that blocks the IL-4 receptor alpha subunit, inhibiting signaling of IL-4 and IL-13 cytokines to reduce type 2 inflammation. Used for Moderate-to-severe atopic dermatitis, Moderate-to-severe asthma with type 2 inflammation, Eosinophilic esophagitis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}